The drug is designed to treat patients with moderate to severe ulcerative colitis or Crohn’s disease who have failed to respond to one more standard therapies.
Entyvio is an integrin receptor antagonist developed by Takeda Pharmaceuticals.
More Articles on Gastroenterology:
GI/Endoscopy Center HIT: The Future is Here
ACGT, AGA, ASGE Meet With CMS to Discuss GI Value & Reimbursement: 4 Things to Know
The 3 Most Exciting Advances in Endoscope Reprocessing
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
